

# Christoph Iking-Konert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6566522/publications.pdf>

Version: 2024-02-01

10  
papers

235  
citations

1040056

9  
h-index

1199594

12  
g-index

12  
all docs

12  
docs citations

12  
times ranked

400  
citing authors

#	ARTICLE	IF	CITATIONS
1	No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany). <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e245-e245.	0.9	17
2	The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis. <i>BMC Rheumatology</i> , 2021, 5, 40.	1.6	6
3	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 33-48.	1.0	13
4	Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study. <i>Viruses</i> , 2019, 11, 186.	3.3	34
5	Changes in the composition of the upper respiratory tract microbial community in granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2019, 97, 29-39.	6.5	41
6	Potential Role for Urine Polymerase Chain Reaction in the Diagnosis of Whipple’s Disease. <i>Clinical Infectious Diseases</i> , 2019, 68, 1089-1097.	5.8	27
7	In situ detection of PR3-ANCA+ B cells and alterations in the variable region of immunoglobulin genes support a role of inflamed tissue in the emergence of auto-reactivity in granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2018, 93, 89-103.	6.5	19
8	Exacerbation of hepatitis E virus infection during anti-TNF $\alpha$ treatment. <i>Joint Bone Spine</i> , 2017, 84, 217-219.	1.6	9
9	ROUTINE – a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. <i>Rheumatology</i> , 2016, 55, 624-635.	1.9	35
10	Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1986-1990.	0.9	25